Ro to offer lower-price vials of weight loss drug Zepbound
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
Eli Lilly (NYSE:LLY) plans to streamline patient access to its weight-loss drug Zepbound by offering single-dose vials ...
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...
Mounjaro and Zepbound. Those drugs brought in a combined $4.4 billion in sales for Lilly in this year's third quarter. The drugmaker plans to start construction of the expansion next year.
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback